Shelley McCloskey
Personalreferent bei XENON PHARMACEUTICALS INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ian Mortimer | M | 48 | 11 Jahre | |
| Clarence Machado | M | 60 | 4 Jahre | |
| Jodi Regts | F | - | 9 Jahre | |
| Sherry Aulin | F | 41 | 13 Jahre | |
| Elizabeth Garofalo | M | 66 | 3 Jahre | |
| Andrea DiFabio | F | 55 | 2 Jahre | |
| Dawn Svoronos | F | 70 | 8 Jahre | |
| Steven Gannon | M | 62 | 9 Jahre | |
| Gary Patou | M | 65 | 20 Jahre | |
| Robin Sherrington | M | 63 | 23 Jahre | |
| Justin Gover | M | 53 | 1 Jahre | |
| James Empfield | M | - | 8 Jahre | |
| Sheila M. Grant | F | - | 4 Jahre | |
| Christopher von Seggern | M | 45 | 4 Jahre | |
| Gillian Cannon | M | 60 | 1 Jahre | |
| Christopher Kenney | M | 53 | 3 Jahre | |
| Michael Rogawski | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Simon Pimstone | M | 56 | 28 Jahre | |
| Frank Holler | M | 67 | 25 Jahre | |
| Michael Hayden | M | 72 | 26 Jahre | |
| Barbara Troupin | M | 56 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Michael Tarnow | M | 79 | 22 Jahre | |
| Mohammad Azab | M | 68 | 21 Jahre | |
| Richard Scheller | M | 70 | 5 Jahre | |
| Richard Levy | M | 66 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Clarissa Desjardins | M | 57 | - | |
| Kelvin Neu | M | 50 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Ernesto Aycardi | M | 61 | 3 Jahre | |
| Abbey Jenkins | F | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | - |
| Alexandra Mancini | F | - | 4 Jahre | |
| Fares Boulos | M | - |
Xantrex Technology, Inc.
 Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | - |
| David Mitchell | M | 67 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 Jahre |
| Paul Brennan | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Stephen Shrewsbury | M | 67 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 Jahre |
| Brad Forth Forth | M | 59 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 3 Jahre |
| Jean-François Heitz | M | 73 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | - |
| Lionel G. Dodd | M | 84 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 3 Jahre |
| Larry D. Sanders | M | 78 |
Xantrex Technology, Inc.
Xantrex Technology, Inc. SemiconductorsElectronic Technology Xantrex Technology, Inc. manufactures power supplies. It specializes in charger and inverter, power inverter, battery charger and backup power. The company is headquartered in Burnaby, Canada. | 4 Jahre |
| Mary Yaroshevsky-Glanville | F | 59 |
1322256 Alberta Ltd.
 1322256 Alberta Ltd. Pharmaceuticals: MajorHealth Technology Inex Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. | 6 Jahre |
| Jason Robertson | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 39 | 97,50% |
| Vereinigte Staaten | 1 | 2,50% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Shelley McCloskey
- Persönliches Netzwerk
